Please login to the form below

Not currently logged in
Email:
Password:

targeting

This page shows the latest targeting news and features for those working in and with pharma, biotech and healthcare.

Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline

Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline

Backed by Novo Holdings, Muna is focused on the development of novel small molecule therapeutics targeting neurodegenerative diseases including Alzheimer’s, frontotemporal dementia and Parkinson’s.

Latest news

More from news
Approximately 2 fully matching, plus 892 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 164 partially matching documents found.

Latest appointments

  • New hires at Abbott, Kite and Arrakis Therapeutics New hires at Abbott, Kite and Arrakis Therapeutics

    Arrakis Therapeutics . Arrakis Therapeutics, a biopharmaceutical company focused on the discovery of new-class small molecules medicines targeting RNA, has appointed Katrine Bosley (pictured below, right) as. ... Katrine’s experience building dynamic,

  • F-star hires ex-BMS immuno-oncology leader

    Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody currently in aphase 1 clinical trial, recruiting the  expansion

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;

  • Industry appointments Industry appointments

    Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.

More from appointments
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 71 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...